All In Biotech

Drug Trial Radar · NCT06708299

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Apr 7, 2025

Primary completion

Sep 21, 2026

Study completion Oct 21, 2026

Sponsor

Lead sponsor
Cardiol Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.

Conditions

  • Recurrent Pericarditis

Interventions

  • CardiolRxDrug

    The intervention will be administered orally (via syringe) with food twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. time to pericarditis recurrenceTime frame: 24 weeks

Locations

27 sites in 4 countries. Site status is shown where the registry gives one.

  • Mayo Clionic Arizona

    Phoenix, Arizona · Recruiting

  • UCI Health

    Irvine, California · Recruiting

  • Altman Clinical and Translational Research Institute

    La Jolla, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Pacific Heart Institute at Cedars-Sinai

    Santa Monica, California · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • MedStar Health Institute

    Columbia, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Minneapolis Heart Institute

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Columbia University - New York Presbyterian

    New York, New York · Recruiting

  • Lenox Hill Hospital

    New York, New York · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

  • University of Utah Hospital

    Salt Lake City, Utah · Recruiting

  • University of Vermont

    Burlington, Vermont · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • Jewish General Hospital

    Montreal, Canada · Recruiting

  • Hippokration General Hospital

    Athens, Greece · Recruiting

  • Fatebenefratelli Hospital Milano

    Milan, Italy · Not yet recruiting

  • University of Padua

    Padua, Italy · Not yet recruiting

  • University Hospital

    Torino, Italy · Not yet recruiting

  • University Hospital Udine

    Udine, Italy · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.